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Perceptions of fecal microbiota transplantation for Clostridium 
difficile infection: factors that predict acceptance
Leslie Parka, Anjali Monea, Jennifer C. Priceb, Demetrios Tzimasa, Jacqueline Hirsha, Michael A. Polesa, 
Lisa Maltera, Lea Ann Chena
NYU Langone Medical Center, NY; University of California, San Francisco, USA
Background Despite the effectiveness of fecal microbiota transplantation (FMT) for treating 
recurrent Clostridium difficile (C. difficile) infection, some patients are reluctant to accept this 
therapy. Our study examined attitudes towards FMT and factors that contribute to patients’ 
acceptance of this treatment.
Methods We distributed patient surveys at a Veterans Affairs hospital, a public hospital, and an 
academic faculty practice. Multivariable logistic regression was performed, adjusting for factors 
associated with FMT acceptance on univariate analysis and prior experience with C. difficile 
infection.
Results Of 267 patients, only 12% knew of FMT prior to the survey, but 77% would undergo the 
procedure if medically indicated. On multivariable analysis, those with children and with college 
degrees or higher were more likely to agree to FMT (odds ratio [OR] 2.11, 95% confidence interval 
[CI] 1.02-4.35; OR 2.27, 95% CI 1.11-4.60 respectively). Sixty-five respondents (71%) chose 
colonoscopy as the preferred vehicle for FMT, while nasogastric tube was least preferred. Disease 
transmission was the most common concern (30%, n=242), and FMT success rate was the least 
selected concern (9.1%).
Conclusions Most patients in a diverse sample of gastroenterology clinics had no prior knowledge 
of FMT, but were receptive to the procedure. Having children and higher education levels were 
predictors for FMT acceptance. Our findings suggest that barriers to FMT utilization may be 
overcome with counseling about safety concerns. More data on the risk of transmitting diseases 
or clinical characteristics, such as obesity, through FMT are needed and will be important for the 
acceptance of this procedure.
Keywords Fecal microbiota transplantation, fecal transplant, FMT, patient perceptions, 
Clostridium difficile
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Introduction
Clostridium difficile (C. difficile) are spore-forming anaerobic 
bacteria [1]. Infection with toxigenic strains of this organism can 
cause a range of effects on its human hosts from asymptomatic 
carriage to life-threatening colitis. Although C. difficile-associated 
diarrhea (CDAD) was traditionally thought to primarily affect 
elderly, hospitalized, or chronically ill patients, the worldwide 
incidence of community-acquired CDAD has increased 
substantially in recent years [2-6]. CDAD can be transmitted 
not only by those with the illness, but probably also through 
asymptomatic carriers and environmental reservoirs [2]. 
Furthermore, there is a rising number of severe cases refractory to 
traditional antibiotic therapy, which has contributed to the increase 
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in C. difficile-related mortality [7-9]. In recent years, CDAD 
has become an increasingly common cause of hospitalization, 
contributing to the burden of rising healthcare costs [9,10].
Fifteen to thirty percent of CDAD patients who initially 
respond develop recurrent disease, and 65% of those patients 
are destined to develop more than one recurrence [11-13]. 
Therapies for recurrent CDAD include antibiotic tapers, pulsed 
antibiotic dosing, anion exchange resins, and administration 
of intravenous immunoglobulins or monoclonal antibodies; 
only limited data are available for all these therapies [14]. FMT 
is the latest treatment option for recurrent CDAD infections 
in patients who have previously failed traditional therapies, 
with a cure rate of approximately 90% [15,16]. During FMT, 
a liquid suspension of healthy donor stool is transplanted into 
an affected patient’s gastrointestinal tract through nasogastric 
tube, enema, or colonoscopy. While the specific mechanism 
by which FMT treats CDAD is unknown, several studies have 
suggested that re-establishment of a diverse gut microbiome is 
key [17-19]. Other studies in mice and humans have shown that 
treatment with a limited number of gut bacteria can also cure 
CDAD, suggesting that transplantation of certain microbial 
functions, rather than merely diversity, is important [20-22].
There are now various case series and one randomized 
control study describing over 500  patients with resistant 
CDAD [23] treated with FMT [16]. While short-term adverse 
effects are limited [15,16], the long-term safety of FMT is 
still largely unknown. Notably, at the time of writing, the 
United States Food and Drug Administration has endorsed 
enforcement discretion for those providing FMT only for 
C. difficile-related indications, though there is no clinical 
indication for which FMT is currently FDA-approved [24].
As with any therapy, uptake of a new treatment modality 
depends not only on its efficacy, but also on physicians’ and 
patients’ perceptions of the therapy. Given the unsavory 
concept of administering donor stool into the colon of a 
recipient, patient and practitioner apprehension may constitute 
barriers to the uptake of FMT. Currently, only a few studies 
have examined the attitudes of the general patient population 
towards FMT. While these studies are important first steps 
in understanding the ultimate acceptance of this emerging 
therapy, the patients studied were limited to single medical 
centers, those who had already undergone FMT, or those 
considering FMT for non-CDAD indications [15,25,26]. Since 
the results of these studies may not reflect the attitudes of a 
broader patient population, we developed a survey to assess 
the interests and concerns regarding FMT for CDAD that was 
distributed to patients from varied ethnic and socioeconomic 
backgrounds. To our knowledge, this is the largest and most 
diverse study to examine patients’ perceptions of FMT.
Materials and methods
Survey development
We designed a survey in the English language to evaluate 
perceptions of FMT and barriers to its recognition as an 
acceptable therapeutic option (see Appendices). The survey 
included the following sections: 1) demographic data; 
2) experience with complementary and alternative medications 
(CAM) and therapies; 3) personal medical history; 4) personal 
history of chronic diarrhea; 5) prior knowledge/experience 
of CDAD; 6) an introduction and description of FMT; and 
7) an assessment of attitudes towards FMT and FMT delivery 
mode. The questions were geared toward discovering factors 
that may influence perceptions of FMT, in addition to general 
demographic data that may be predictive of acceptance of FMT.
Study participants and recruitment
Surveys were distributed over a 10-month period in the 
waiting areas of adult gastroenterology clinics of an urban 
public hospital (Bellevue Hospital Center), an urban Veterans 
Affairs hospital (New  York Harbor Healthcare System-
Manhattan Campus), and in faculty practices affiliated with 
New  York University’s Langone Medical Center, all located 
in New  York City. Surveys were completed by and collected 
from patients waiting for their appointments. Participation 
was voluntary and anonymous; the participants were not 
compensated. Review board approval was waived at all 3 
participating hospitals.
Statistical analysis
Statistical calculations were performed using STATATM 
12.1 software (StataCorp). Unanswered questions were 
omitted from the analysis. Pearson χ2 analysis was used to 
evaluate univariate factors associated with FMT acceptance. 
Factors that accounted for FMT acceptability with P<0.10 on 
univariate analysis were analyzed by multivariable logistic 
regression. In addition, the existence of either first- or second-
hand experience with C. difficile infection was also included in 
our model, given its presumed influence on FMT acceptability. 
For all analyses, a P-value <0.05 was considered statistically 
significant.
Results
A total of 267 adult patients were surveyed across all 
clinical sites (Table  1). Overall, 12% (29/234) of respondents 
were aware of FMT prior to the survey and 77% (163/213) of 
all of the subjects would undergo the procedure if medically 
indicated. Twenty-nine percent knew of C. difficile before the 
survey, with 4% reporting a personal history of CDAD. Eight 
percent of patients reported a friend or family member who 
had suffered from the illness. Nine percent reported a personal 
history of chronic diarrhea.
Fifty-six percent of respondents reported a history of CAM 
use (such as acupuncture, Ayurvedic medicine, colonics, 
chiropractic medicine, homeopathy, or traditional Chinese 
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medicine). Thirty-two percent of respondents reported current 
or prior use of probiotics, half through pill formulations and 
half through yogurts. Of those using probiotics, 5% did so as 
therapy for chronic diarrhea and 26% for overall health.
On univariate analysis, subjects with children and those 
with at least a university degree were more likely to agree to 
FMT (81% vs. 69%, P=0.04; 81% vs. 68%, P=0.03, respectively). 
Other factors, including a history of chronic diarrhea, use 
of CAM or probiotics, or prior experience with C. difficile 
infection, were not found to be significantly associated with 
FMT acceptability. There was a trend towards willingness 
to undergo FMT among those who were married versus 
unmarried (85% vs. 73%, P=0.06).
On multivariable analysis, we accounted for variables found 
to be significant at a P<0.10 level on univariate analysis; these 
included having children, being married, and having at least a 
college level education. In addition, we accounted for first or 
second hand experience with C. difficile infection in our model. 
Again, respondents with children and those with college 
degrees or higher were more likely to accept FMT (odds ratio 
[OR] 2.11, 95% confidence interval [CI] 1.02-4.35, P=0.04; OR 
2.27, 1.11-4.60, P=0.02, respectively) (Table 2).
Our survey, which included a brief primer on FMT delivery 
modalities, also evaluated which modalities would be preferred 
by patients. When asked to rank FMT delivery by nasogastric 
tube (NGT), enema, or colonoscopy, 71% of respondents 
ranked colonoscopy as the most acceptable vehicle for stool 
transplant, while NGT was the least preferred.
We then evaluated possible sources of the negative 
perceptions of FMT. Disease transmission was the most 
commonly cited concern (30%, 72/242). Other concerns 
included fear of the delivery procedure required for FMT (21%, 
50/242) and the “dirty/unsanitary” perception of FMT (22%, 
53/241). The success rate of the fecal transplant was the least 
selected concern (9.1%) (Fig. 1).
Discussion
FMT is an effective treatment for recurrent CDAD [15,16]. 
However, as with other procedures, such as screening 
colonoscopies, effectiveness may be tempered by patient 
acceptance [27]. There are currently few studies in the literature 
that evaluate patient perceptions of this emerging therapy. Our 
study expands upon this literature in both the number and 
breadth of the patients evaluated, as it was conducted across 
clinic sites for 3 distinct hospitals that together serve patients 
from a large range of socioeconomic, educational, and cultural 
backgrounds. Furthermore, we explored the factors that 
motivate acceptance or rejection of this therapy.
Our results show that, despite its inherently unappealing 
aspects, most patients are open to FMT as a therapeutic option 
for recurrent CDAD. This is similar to the findings of Kahn 
et al [29], who published the first study investigating patient 
attitudes towards FMT, evaluating it in the context of treating 
ulcerative colitis (UC). Using focus groups, the investigators 
interviewed 15 adults with UC and 7 parents of children with 
UC and found them willing to pursue FMT for themselves 
or their child as an adjunct to standard UC treatments. 
Interestingly, in another study of UC patients (n=95) by Kahn 
et al [26], the majority were willing to consider FMT despite 
satisfactory disease control with their current conventional 
treatments. In fact, patients identified safety and efficacy as 
the most important factors in choosing FMT as a therapeutic 
option, followed by the need for surgery and their physician’s 
recommendation. As expected, patients with previous 
hospitalizations for UC and severe disease showed a greater 
interest in FMT. In our study, FMT efficacy was the least selected 
concern regarding the therapy. While this may be appropriate 
regarding FMT for CDAD indications, it is worth noting that 
early efficacy data on FMT for other diseases, while promising, 
are far more modest [28-30]. In line with such findings, at 
the time of this writing, the Federal Drug Administration is 
exercising enforcement discretion regarding Investigational 
New Drug (IND) applications for the clinical use of FMT for 
C. difficile not responding to standard therapies [31]. However, 
an IND is required for all other indications.
Also in 2012, Zipursky et al [25] utilized structured 
surveys, including hypothetical case scenarios, to investigate 
perceptions of FMT for recurrent CDAD in general medicine 
patients, the majority of whom had not suffered from CDAD 
Table 1 Demographics of survey participants
Sites
VA clinic 50% (133/267)
Faculty group practice 28% (75/267)
Public hospital 22% (59/267)
Male 65% (170/260)
English as primary language 88% (229/261)
Race (self-identified)
White 54% (139/256)
Black 23% (59/256)
Asian 7.8% (20/256)
Other 14% (38/256)
Education
Did not complete high school 7.5% (20/266)
High school 26% (68/266)
Vocational school 4.5% (12/266)
College 40% (105/266)
Graduate school 23% (61/266)
Income (K/year)
<25 40% (94/238)
25-49 27% (63/238)
50-74 18% (42/238)
75-99 5.9% (14/238)
>100 11% (24/238)
Have children 62% (160/264)
K, US$1000
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or had the procedure previously. In this single-center study, the 
majority of subjects were white (93.5%) and female (70%). In 
contrast, our respondents included 23% black, 27% Hispanic, 
and 7.8% Asian patients, reflecting our large metropolitan 
environment. Our study was also predominantly male (65%). 
Regardless of the cultural differences between the two study 
populations, as well as the growing use of FMT, both studies 
indicate a lack of knowledge about FMT in the community, 
with only approximately 10% of respondents being aware 
of the therapy prior to survey completion. In addition, both 
studies found that a majority of individuals would undergo the 
procedure if medically indicated. Thus, despite the differences 
in sex and ethnicity distributions, patients’ perceptions of stool 
transplantation are comparable.
Our findings further provide interesting insight into the 
potential factors that may influence patient acceptance of fecal 
transplant. On univariate and multivariable analyses, having 
children was a significant predictor for accepting FMT. It is 
possible that patients with children are more likely to embrace 
a treatment that is inherently unappealing in nature because of 
their drive to provide for their family. This hypothesis is further 
supported by our results showing a trend toward accepting 
FMT among those married versus unmarried. A  similar 
impact of familial relationships on the acceptance of medical 
procedures has also been found in the colon cancer screening 
literature [32-35]. For example, Kotwal et al found higher 
screening colonoscopy rates among married versus unmarried 
men. Also, husbands were more likely to obtain colonoscopies 
if they described their wives as happy with their marriage, 
more highly educated, and more supportive [35].
In our study, at least 63% of patients had university or 
graduate degrees. This level of education was found to be 
a significant predictor of FMT acceptance on univariate 
and multivariable analyses, suggesting that education and, 
presumably greater health literacy, plays an important role in 
FMT acceptance. Each of the prior studies of FMT acceptability 
also identified a positive correlation between higher education 
level and increased acceptance rates. Prior studies have also 
shown that knowledge of alternative medicine is correlated 
with the level of education [36,37]. While the majority of 
study respondents (56%) had personal experience with using 
probiotics or CAM, the use of such therapies did not correlate 
with FMT acceptance in our study.
One of the barriers to FMT uptake is the “yuck factor” 
associated with internalizing a filthy product. Though our 
study respondents were concerned that the administered stool 
was “dirty” (22%) and feared the procedure (21%), the most 
common patient concern was about disease transmission 
(30%). While the current literature does not support any 
significant disease transmission in FMTs [38], transmission of 
currently unrecognized infectious agents remains a possibility 
and is an important area for continued research.
Consideration must also be given to the mechanism of 
donor stool delivery. Our findings suggest a preference for 
colonoscopy as the most acceptable vehicle for stool transplant 
and NGT as the least acceptable. However, there are still practical 
barriers to these delivery modalities as they are invasive, 
unpleasant, and have the potential for complications [15]. 
Studies exploring more esthetically appealing, less invasive and 
easier methods for administration of FMT are ongoing. In a 
small pilot study (n=20), Youngster et al demonstrated 90% 
clinical resolution of recurrent CDAD after oral administration 
of frozen capsules of fecal material from unrelated donors [39]. 
There were no serious or unexpected adverse events. This new 
FMT delivery modality may help promote the availability 
of FMT, as it eliminates the need for patients and medical 
providers to handle stool suspensions and obviates the need 
for a gastrointestinal procedure.
Table 2 Logistic regression analyses of variables affecting FMT acceptability
Willingness to undergo FMT Univariate odds ratio (P-value, 95%CI) Multivariable odds ratio (P-value, 95%CI)
Respondents with children 1.95 (P=0.04, 1.02-3.69) 2.11 (P=0.04, 1.02-4.35)
Married 2.04 (P=0.07, 0.95-4.39) 1.54 (P=0.30, 0.68-3.46)
College or graduate education 2.08 (P=0.03, 1.09-3.95) 2.27 (P=0.02, 1.11-4.60)
Experience with C. difficile* 1.57 (P=0.22, 0.758-3.24) 1.48 (P=0.32, 0.68-3.22)
*Either personally or through a friend or relative. While Clostridium difficile (C. difficile) experience was found to have a P value > 0.10 on univariate analysis, 
it was included in our multivariable regression analysis because of its presumed influence on FMT acceptability 
FMT, fecal microbiota transplantation; CI, confidence interval
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perceptions
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Finally, another barrier to the widespread utilization of 
FMT to treat complicated CDAD is apprehension amongst 
physicians [40]. While not addressed in our study, investigation 
into physician attitudes reveals a lack of knowledge about the 
procedure itself, a misperception about patient attitudes toward 
FMT, and an aversion for handling stool during the treatment, 
with up to 29% of physicians reporting it was unappealing 
enough to prevent them from offering this therapy despite 
positive reported data [41].
Our study has some limitations. Since the survey was only 
distributed in English, it is difficult to draw conclusions on 
the views of immigrant patient populations with potential 
language barriers receiving healthcare in the United States. In 
addition, the education level and literacy of our patients may 
have affected their ability to fully complete and understand 
a somewhat lengthy study survey. Those who had difficulties 
reading or understanding English, regardless of reason, may 
have had difficulties understanding certain questions. This 
may have contributed to the unanswered questions on the 
survey, though some questions were left unanswered because 
of time limitations. Finally, our surveys only evaluated patients’ 
attitudes; they did not assess physicians’ attitudes toward FMT 
and their possible contribution to the barriers against FMT 
utilization.
In conclusion, FMT is an effective treatment modality for 
recurrent CDAD and may have significant application in other 
major diseases, including metabolic syndrome, inflammatory 
bowel disease, and other autoimmune conditions. Despite 
limited prior knowledge of FMT and concerns about safety, 
patients are receptive to the procedure, highlighting a role 
for shared decision-making when considering this emerging 
therapy. Attitudes toward FMT are modifiable barriers to 
the wide-scale use of this therapy in the CDAD treatment 
armamentarium. Furthermore, advancements in the delivery 
method, such as encapsulation of donor stool, may further 
improve FMT’s safety and acceptability.
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